A Phase 2/3 interventional study of Dexamethasone ophthalmic suspension (OCS-01) and Vehicle in Diabetic Macular Edema, sponsored by Oculis. Completed at 52 sites in 4 countries. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2026-05-05.
Sponsored by Oculis · Phase 2/3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 56 studies testing dexamethasone in Macular Edema — 3 open to participants now, 3 under way, 1 of them phase 3. Dexamethasone · Macular Edema.
Among the 56 studies testing dexamethasone in Macular Edema, this one is the 6th largest by enrollment of the 55 interventional ones that give a count, is one of 4 that started in 2021, is one of 2 in phase 2/3, and was the 50th registered.
758 studies on the registry are indexed under Macular Edema; 66 are open to participants now.
Browse Macular Edema studies →3 of the 56 studies testing dexamethasone in Macular Edema are open now, in 2 countries. Recruiting first, the newest first:
Tianjin Medical University Eye Hospital · Sites in China
Ages 18+
Massachusetts Eye and Ear Infirmary · Sites in United States
Ages 18–85
Affiliated Hospital of Nantong University · Sites in China
By country, each count listing its studies:
Dexamethasone: first FDA approval 1958 (DECADRON), first EMA approval 2010. What it is approved for, and how studies give it, is on its page →
Of the 44 Macular Edema studies recruiting now, 31 (70%) set no upper age limit and 7 (16%) stop at 75 or younger; 1 takes children under 18; 2 take healthy volunteers.
This study: 18 Years to 85 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
56 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 16 · Phase 3 16 · Phase 4 18
First in 2004; this study’s year is marked. 4 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 552 is above the median of 56 across 586 interventional studies indexed under Macular Edema.
Median enrollment 50 across the 55 interventional studies. Of the 50 that completed or were terminated, 29 (58%) have results posted.
This tab as a report to print or save as PDF → With an account.
17 of 56 have an industry lead sponsor. The 10 most frequent:
Oculis is the lead sponsor of 10 studies on the registry; 1 is open to participants now.
Of its 7 completed or terminated interventional studies of FDA-regulated products, 4 (57%) have results posted.
Oculis has 3 studies filed under Macular Edema — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 56 studies testing dexamethasone in Macular Edema, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The primary objective of this study is to evaluate the efficacy and safety of the topical ophthalmic administration of OCS- 01 as compared to Vehicle in participants with Diabetic Macular Edema (DME).
A Phase 2/3 Pivotal Double-masked, Randomized, Vehicle-controlled, 2 stage, Multicenter Study of the Efficacy and Safety of OCS-01 Eye Drops in Participants with Diabetic Macular Edema
Stage 1: To select a dose and dosing regimen for OCS-01 in participants with DME and evaluate the efficacy and safety of OCS-01 as compared to Vehicle in participants with DME.
Stage 2: To evaluate the efficacy and safety of OCS-01 as compared to Vehicle at Week 52 in participants with DME.
Inclusion Criteria (selection) - Stage 1:
Inclusion Criteria (selection) - Stage 2:
Exclusion criteria (selection) - Stage 1 and Stage 2:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
dexamethasone ophthalmic suspension,1.5% \[15 mg/ mL\]
Drug: Dexamethasone ophthalmic suspension (OCS-01)
Placebo is a Vehicle ophthalmic suspension of OCS-01
Drug: Vehicle
Stage 1: Participants will be dosed with one eye drop of OCS-01 6 times per day for 6 weeks (induction phase) followed by 3 times per day for 6 weeks (maintenance phase). Stage 2: Participants will be dosed with one eye drop of OCS-01 6 times per day for 6 weeks (induction phase) followed by 3 times per day for 46 weeks (maintenance phase).
Also known as: Dexamethasone
Stage 1: Participants will be dosed with one eye drop of vehicle 6 times per day for 6 weeks (induction phase) followed by 3 times per day for 6 weeks (maintenance phase). Stage 2: Participant will be dosed with one eye drop of vehicle 6 times per day for 6 weeks (induction phase) followed by 3 times per day for 46 weeks (maintenance phase).
Also known as: Placebo
Mean Change in BCVA (Best Corrected Visual Acuity)
Assessed using ETDRS (Early Treatment Diabetes Retinopathy Study) letters score: higher numbers on the ETDRS chart representing better visual acuity
Time frame: Week 52
Percentage of Participants with a 3-line or Greater Gain in BCVA
BCVA will be assessed by ETDRS letters score: higher numbers on the ETDRS chart representing better visual acuity.
Time frame: Baseline, Week 52
Mean Change in BCVA
BCVA will be assessed using ETDRS letters score: higher numbers on the ETDRS chart representing better visual acuity.
Time frame: Baseline, Week 12 and Week 24
Mean Change in Central Subfield Thickness (CST)
CST will be measured by SD-OCT.
Time frame: Baseline, Week 52
Number of Participants With Treatment Emergent Adverse events (TEAEs)
An adverse event (AE) is defined as any untoward medical occurrence in a clinical investigation participant. TEAEs are those AEs that occur after administration of the study product and are therefore temporally associated with the use of the study product.
Time frame: Up to Week 52
Plan to share: No
No publications or documents are linked to this record.
Ran from Oct 2021 to primary completion in Apr 2026, 53 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Dexamethasone
Oculis